Our Story

Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions
09.15.2020

Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions

view full story

Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors
09.09.2020

Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors

view full story

Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans To Board Of Directors
09.09.2020

Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans To Board Of Directors

view full story

Nimbus Therapeutics Appoints Veteran Pharmaceutical Chemist Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry
09.01.2020

Nimbus Therapeutics Appoints Veteran Pharmaceutical Chemist Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry

view full story

Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
08.27.2020

Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

view full story

Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
08.25.2020

Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

view full story

Protagonist Appoints Sarah O'Dowd to Board of Directors
08.13.2020

Protagonist Appoints Sarah O’Dowd to Board of Directors

view full story

Forma Therapeutics Elects Distinguished Researcher And Physician Wayne A.I. Frederick, M.D., To Board Of Directors
07.30.2020

Forma Therapeutics Elects Distinguished Researcher And Physician Wayne A.I. Frederick, M.D., To Board Of Directors

view full story

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
07.09.2020

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

view full story

Forma Therapeutics Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares
06.23.2020

Forma Therapeutics Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares

view full story

Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo
06.22.2020

Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo

view full story

Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
06.17.2020

Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera

view full story

Forma Therapeutics Presents Safety, Pharmacokinetic And Pharmacodynamic Data From Phase 1 Clinical Trial For Investigational Agent FT-4202 In Patients With Sickle Cell Disease
06.12.2020

Forma Therapeutics Presents Safety, Pharmacokinetic And Pharmacodynamic Data From Phase 1 Clinical Trial For Investigational Agent FT-4202 In Patients With Sickle Cell Disease

view full story

Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism
06.08.2020

Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism

view full story

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis
06.03.2020

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis

view full story

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
05.26.2020

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

view full story

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
05.20.2020

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

view full story

Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
05.15.2020

Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting

view full story

Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity
05.15.2020

Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity

view full story

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
05.07.2020

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

view full story

Forma Therapeutics Appoints David N. Cook, Ph.D., To Chief Scientific Officer
04.28.2020

Forma Therapeutics Appoints David N. Cook, Ph.D., To Chief Scientific Officer

view full story

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
04.23.2020

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388

view full story

Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity Of A Potent And Selective Inhibitor Of CBP/P300 For Androgen Receptor Positive Cancers To Be Presented At The American Association For Cancer Research
04.21.2020

Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity Of A Potent And Selective Inhibitor Of CBP/P300 For Androgen Receptor Positive Cancers To Be Presented At The American Association For Cancer Research

view full story

FORMA Therapeutics Receives FDA Orphan Drug Designation For FT-4202 For The Treatment Of Sickle Cell Disease
4.15.2020

FORMA Therapeutics Receives FDA Orphan Drug Designation For FT-4202 For The Treatment Of Sickle Cell Disease

view full story

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
4.8.2020

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

view full story

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
3.17.2020

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

view full story

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
3.12.2020

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

view full story

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
3.12.2020

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

view full story

FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation And Rare Pediatric Disease Designation For Treatment Of Sickle Cell Disease
2.20.2020

FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation And Rare Pediatric Disease Designation For Treatment Of Sickle Cell Disease

view full story

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis
2.11.2020

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

view full story

FORMA Reports Achievement Of Early-Stage Clinical Development Milestones For Assets Licensed Exclusively To Boehringer Ingelheim And Bristol-Myers Squibb
1.30.2020

FORMA Reports Achievement Of Early-Stage Clinical Development Milestones For Assets Licensed Exclusively To Boehringer Ingelheim And Bristol-Myers Squibb

view full story

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
01.13.2019

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

view full story

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
01.07.2020

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

view full story

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
01.06.2020

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

view full story